Quanterix receives $18.2M NIH contract for COVID-19 antigen test

Quanterix has entered into a Phase 2 contract with the National Institutes of Health worth $18.2 million to develop, scale up and deploy a SARS-CoV-2 antigen test based on its Simoa technology. The contract runs through September 2021.

“The need for accurate and reliable testing in response to the global COVID-19 pandemic continues, and we are honored to have been selected by the NIH to progress to Phase 2 of this important initiative.”businesswire.com

• 1 source
• businesswire.comQuanterix Receives National Institutes of Health RADx Contract to Advance Antigen Test for SARS-CoV-2 (COVID-19)Media ContactOct 6, 2020

Summarized from public sources; check the original articles before acting on it.